FDA Expands Approval for Jylamvo to Children With Acute Lymphoblastic Leukemia
The Food and Drug Administration (FDA) expanded the approval of Jylamvo (methotrexate) to include children with acute lymphoblastic leukemia, marking it as the only oral liquid formulation of methotrexate for both adults and children.
Comentarios